Breaking News
0

Akari Therapeutics PLC (AKTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Akari Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.730 -0.060    -3.35%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
1.760
+0.030
+1.734%
17:29:27 - Real-time Data
Type: Equity
Market: United States
ISIN: US00972G1085 
CUSIP: 00972G108
  • Volume: 253,609
  • Bid/Ask: 1.700 / 1.900
  • Day's Range: 1.720 - 1.800
Akari Therapeutics 1.730 -0.060 -3.35%

AKTX Overview

 
This is the main Akari Therapeutics PLC stock chart and current price. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close1.79
Day's Range1.72 - 1.8
RevenueN/A
Open1.77
52 wk Range1.56 - 9.2
EPS - 0.87
Volume253,609
Market Cap36.53M
Dividend (Yield)N/A (N/A)
Average Vol. (3m)1,104,688
P/E RatioN/A
Beta - 2.88
1-Year Change - 1.1%
Shares Outstanding1,650,693,413
Next Earnings DateNov 11, 2019
What is your sentiment on Akari Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Akari Therapeutics PLC News


Akari Therapeutics PLC Analysis


Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Strong Sell Strong Sell Strong Sell Strong Sell Strong Sell
Technical Indicators Strong Sell Strong Sell Strong Sell Strong Sell Strong Sell
Summary Strong Sell Strong Sell Strong Sell Strong Sell Strong Sell

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Bullish doji Star 5H Current
Harami Cross 1M Current
Completed Patterns
Bullish Engulfing 1M 2 Aug 19
Bullish doji Star 1D 2 Oct 11, 2019
Tri-Star Bearish 30 2 Oct 15, 2019 02:30PM

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Apple 235.32 237.65 234.88 -0.55 -0.23% 21.69M 15:59:59  
  Amazon.com 1,767.38 1,776.45 1,740.62 +30.95 +1.78% 3.10M 15:59:59  
  Bank of America 29.73 30.24 29.11 +0.59 +2.02% 78.20M 15:59:59  
  NVIDIA 196.37 199.29 189.60 +9.84 +5.28% 16.58M 15:59:59  
  Coca-Cola 53.51 53.68 53.27 +0.21 +0.39% 8.47M 15:59:59  
  Microsoft 141.58 141.79 139.81 +2.02 +1.45% 19.44M 15:59:59  
  Tesla 257.89 260.00 254.12 +0.93 +0.36% 6.43M 15:59:59  
  Sangamo Therapeutics 8.40 8.45 7.94 +0.37 +4.61% 3.65M 15:59:59  
  Alibaba ADR 175.29 176.75 172.69 +4.13 +2.41% 13.72M 15:59:59  
  Viking Therapeutics Inc 6.620 6.650 6.385 +0.220 +3.44% 1.01M 15:59:59  

Akari Therapeutics PLC Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

13

Equity Type

ADR

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) $0 Start Trading
National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States) $500 Start Trading
Securities Investor Protection Corporation (United States) $0 Start Trading
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AKTX Comments

Write your thoughts about Akari Therapeutics PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Joseph Mission
Joseph Mission Oct 11, 2019 1:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Holddddd!
KEN LNSS
KEN LNSS Oct 02, 2019 2:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sell
Piter Max
Piter Max Mar 15, 2019 10:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hold or Sell???
Eddie Amar
Eddie Amar Mar 15, 2019 10:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sell.,. I sold in the morning, . lost some money
Piter Max
Piter Max Mar 14, 2019 12:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy or sell??
Piter Max
Piter Max Mar 14, 2019 10:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
FDA
Piter Max
Piter Max Mar 14, 2019 9:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics's Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
jacob capeles
jacob capeles Mar 14, 2019 9:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why u say that
Piter Max
Piter Max Mar 14, 2019 8:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
crazy people!!
Ashraf Sorathiya
Ashraf Sorathiya Mar 14, 2019 6:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will hit 9
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email